{"schema_version":"secwatch.filing_event.v1","accession":"0001558370-24-004601","form_type":"8-K","ticker":"BPTH","cik":"0001133818","company_name":"BIO-PATH HOLDINGS, INC.","filed_at":"2024-04-02T23:59:59+00:00","discovered_at":"2026-05-14T18:03:17.406853+00:00","generated_at":"2026-06-04T03:18:47.530088+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Bio-Path provides 2024 clinical update: AML, solid tumor trials advancing","bullets":["Phase 2 prexigebersen trial in AML targets FDA Fast Track for fragile patients; median survival 5-10 months.","Phase 1/1b BP1001-A in solid tumors advanced to second dose level; Phase 1b with paclitaxel planned.","Phase 1/1b BP1002 in relapsed/refractory AML enrolling at 40 mg/m2; no DLTs at 20 mg/m2.","Phase 1 BP1002 in lymphoma/CLL enrolling second dose cohort (40 mg/m2) after no DLTs.","Patent portfolio: 5 US and 53 foreign issued patents covering DNAbilize technology."],"urls":{"canonical":"https://secwatch.observer/filing/0001558370-24-004601","json":"https://secwatch.observer/filing/0001558370-24-004601.json","markdown":"https://secwatch.observer/filing/0001558370-24-004601.md","text":"https://secwatch.observer/filing/0001558370-24-004601.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1133818/000155837024004601/0001558370-24-004601-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1133818/000155837024004601/bpth-20240402x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-04T03:18:47.530088+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}